Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A double-blind, between-patient, comparative trial of diclofenac (Voltaren) and naproxen was carried out in 30 patients suffering from osteo-arthrosis of the hip or the knee. The drugs were given twice daily, morning and evening, during a period of two weeks. The daily dose was 100 mg for Voltaren and 500 mg for naproxen. The results indicate that Voltaren brought relief of pain and stiffness in a greater number of patients than did naproxen. The same finding was made regarding the influence on the range of joint movements, the difference reaching statistical significance. Voltaren appeared also to be better tolerated since the number of patients reporting side-effects was smaller and the complaints of less severity.
 ...
PMID:Diclofenac (Voltaren) for the treatment of osteo-arthrosis: a double-blind comparison with naproxen. 33 Feb 88

In a double-blind comparison with placebo in 60 patients suffering from post-operative pain following the surgical removal of a third molar in the lower jaw, statistical analyses showed that Voltaren (diclofenac sodium) in a single dose of 50 mg had a significantly greater analgesic effect than placebo. The technique to be used for studies with analgesic drugs is briefly discussed.
 ...
PMID:A clinical trial of the analgesic properties of Voltaren (diclofenac sodium). 35 44

In a double-blind crossover trial conducted on a multicentre basis, 109 patients with "classic" or "definite" rheumatoid arthritis were treated for two weeks with diclofenac sodium (Voltaren, 25 mg t.i.d.) and indomethacin (25 mg t.i.d). Both drugs led to a clear-cut decrease in morning stiffness, as well as to a significant improvement in pain at rest and on movement. In these respects no significant difference between the two-drugs was observed. As regards their effect on status of rheumatoid condition, however, a trend towards a significant improvement was discernible, in the investigator's opinion, only in response to diclofenac sodium. "Unwanted effects" were mentioned by 25 patients before the trial, by 31 during treatment with diclofenac sodium, and by 33 during treatment with indomethacin. While the patients were receiving indomethacin, five of them discontinued treatment on account of side effects (headache in three cases, headache and tiredness in one case, and an allergic skin reaction in one case) and one of them, who complained of headache, lowered the dosage; treatment with diclofenac sodium was discontinued because of side effects by only one patient, who had developed an allergic skin reaction.
 ...
PMID:Diclofenac sodium (Voltaren) and indomethacin in the ambulatory treatment of rheumatoid arthritis: a double-blind multicentre study. 35 46

In a double-blind, between-patient trial the efficacy and tolerability of two new non-steroid anti-inflammatory analgesics-diclofenac sodium (Voltaren) 50 mg b.i.d. and naproxen 250 mg b.i.d.-were compared in hospitalised patients with rheumatoid arthritis. Both drugs had a clearly positive effect on the duration of morning stiffness, bilateral grip strength, pain at rest, and pain on movement. No statistically significant difference between the two drugs was found with respect to clinical efficacy. Three patients treated with diclofenac sodium reported unwanted effects, as compared with seven patients receiving naproxen. These unwated effects led to premature discontinuation of the treatment in one patient on naproxen. Thus, although both drugs were well tolerated, it appeared that diclofenac sodium caused somewhat fewer unwanted effects.
 ...
PMID:Diclofenac sodium (Voltaren) and naproxen in the treatment of rheumatoid arthritis: a comparative double-blind study. 35 47

In a double-blind study, diclofenac sodium (Voltaren)--administered for 14 days in a dosage of 25 mg t.i.d.--was compared with naproxen (250 mg b.i.d. for 14 days) in the treatment of 120 patients with soft-tissue rheumatism. Assessment of the efficacy of the two treatments was based upon changes, recorded once a week, in the following parameters: pain at rest and on movement, swelling, local tenderness, functional impairment, limitation of movement, and sleep disturbances. The incidence of unwanted effects was also recorded, and the effects themselves were classified according to the probability of their being causally related to the trial preparations. Both drugs appeared to be effective in relieving symptoms associated with soft-tissue rheumatism. In most indications the therapeutic efficacy of the two preparations was similar. In patients suffering from diseases affecting the shoulder region, however, diclofenac sodium was significantly more effective. Unwanted effects rarely occurred with either drug.
 ...
PMID:A comparative short-term trial with Voltaren (diclofenac sodium) and naproxen in soft-tissue rheumatism. 35 49

Two non-steroidal antirheumatic drugs, diclofenac (Voltaren) and naproxen (Proxen), were compared with respect to their analgesic effect and the observed improvement in joint mobility in two groups of patients, each consisting of 20 males with either cox-arthrosis or gonarthrosis. The duration of treatment was up to six months. The therapeutic response was assessed by the mean scores of spontaneous and exercise-induced pain, the clinical state of joints and painfree time of walking. Both drugs led to a persistent improvement in the condition of most patients, but the clinical impression would appear to point to a more marked analgesic effect of diclofenac. The daily maintenance dosage from the fourth week of treatment onwards was 75 mg diclofenac and 500 mg naproxen. Both drugs were generally well tolerated. Occasionally gastrointestinal side effects were observed (more frequently in the naproxen group). Laboratory controls were carried out periodically, but no evidence of organ toxicity or hemotoxic effects was found.
 ...
PMID:[Long-term comparative study: diclofenac (voltaren) and naproxen (proxen) in arthritis]. 62 55

In a multicentric, interindividual, double-blind study, the analgesic action, duration of effect, tolerability and side effects of the new combination preparation, Combaren (diclofenac-Na 50 mg+codeine phosphate 50 mg), were compared with those of diclofenac-Na 50 mg (Voltaren 50) in 184 patients with severe tumor-related pain. The results show that Combaren is a highly effective preparation for the treatment of severe tumor pain. The combination of diclofenac-Na with codeine phosphate leads to a clear, statistically significant, augmentation of the effectiveness of additionally used analgesics on pain severity, and the general effectiveness of the combination is more positively assessed that that of monotherapy with diclofenac (also effective). In the staged approach to the treatment of malignancy-related pain in which the aim is to provide continuous, preventive analgesia rather than ad hoc treatment of newly developing or worsening pain, this combination preparation will presumably find a permanent place in stage I/II of the generally accepted staged pain-treatment scheme.
 ...
PMID:[Drug therapy in severe tumor pain. Comparative study of a new combination preparation versus diclofenac-Na]. 138 30

Following several years of development and validation, we applied the WOMAC Osteoarthritis Index as the principal outcome measure in a double blind randomized parallel trial of Meclomen (100 mg po tid) and Voltaren (25 mg po tid). Statistically significant improvements in clinical status were noted in both treatment groups. At the doses studied, between drug differences favoring Meclomen were observed in pain and stiffness, no difference being noted in physical function. No significant between drug difference was noted in tolerability at these same doses. Our study also demonstrated that the relative efficiency of WOMAC was similar to that of the Lequesne and Doyle indices. Finally, we defined the standard deviation necessary to calculate sample size for future studies using the WOMAC index, both for studies based on static scores and those based on change scores.
 ...
PMID:Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index. 155 79

The preoperative single-dose oral administration of a combination of rapid- and slow-release diclofenac (Voltaren, Ciba-Geigy, Basel, Switzerland) preparation in a placebo-controlled trial proved to be more effective in postoperative pain prevention following third molar removal than the combination of intramuscular diclofenac and an oral depot formula.
 ...
PMID:Postoperative pain prevention by a single-dose formulation of diclofenac producing a steady plasma concentration. 173 85

Diclofenac sodium suppositories 150-200 mg day-1 were compared with placebo in a double-blind study during the first 3 days after uvulopalatopharyngoplasty in 40 patients with habitual snoring or obstructive sleep apnoea syndrome. Consumption of rescue analgesics (paracetamol suppositories) and pain assessed by a visual analogue scale were significantly less in the diclofenac group. Bleeding time (modified Ivy's test) and reported side effects did not differ between the two groups.
 ...
PMID:Treatment of postoperative pain with diclofenac in uvulopalatopharyngoplasty. 173 73


1 2 3 4 5 6 7 8 9 Next >>